133 results
8-K
EX-99.1
SRZN
Surrozen Inc
8 May 24
Surrozen Provides First Quarter 2024 Financial Results and Business Update
4:12pm
, the potential for such product candidates to be used to treat human disease, as well as the potential
benefits of such product candidates
424B5
SRZN
Surrozen Inc
25 Apr 24
Prospectus supplement for primary offering
4:28pm
of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.
In general, Section 203
8-K
EX-10.4
hof5 hxhr7iw40tdl
2 Apr 24
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-10.1
f050g
2 Apr 24
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-10.2
794qghotw
2 Apr 24
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-10.3
1lnqzw5mbcdy bc0h
2 Apr 24
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-10.6
dv586z0p
2 Apr 24
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-10.5
t8i gx1c3k
2 Apr 24
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-99.1
pw1s975x0dznxp1vhs2
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
424B3
18t8msfm 5tf3uc
8 Nov 23
Prospectus supplement
4:27pm
424B3
g7z5924l92d 57xq2jxl
9 Aug 23
Prospectus supplement
4:39pm